Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome

BMC Gastroenterology

Research Article

Chara Tzavara¹  Anastasia Kapsoritaki²  Andreas N Kapsoritakis²  Spyros P Potamianos²  Anastassios C Manolakis²  Varvara Valotassiou³  Panagiotis Georgoulias³ 

[1] Center for Health Services Research, University of Athens, School of Medicine, 11527, Athens, Greece;Department of Gastroenterology, University of Thessaly, School of Medicine, 41110, Larissa, Greece;Laboratory of Nuclear Medicine, University of Thessaly, School of Medicine, 41110, Larissa, Greece;

关键词: Inflammatory Bowel Disease;    Ulcerative Colitis;    Irritable Bowel Syndrome;    Inflammatory Bowel Disease Patient;    Irritable Bowel Syndrome Patient;   

DOI  :  10.1186/1471-230X-10-118

 received in 2010-04-28, accepted in 2010-10-14,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundS100A12, a calcium-binding proinflammatory protein secreted by granulocytes, has been associated with different diseases of inflammatory origin, including inflammatory bowel disease (IBD). In this study, the utility of serum S100A12, in discriminating IBD from irritable bowel syndrome (IBS), was tested.MethodsS100A12 serum levels were determined in 64 patients with ulcerative colitis (UC), 64 with Crohn's disease (CD) and 73 with IBS, by means of an enzyme-linked immunosorbent assay. S100A12 serum levels were evaluated with respect to the levels of known inflammatory markers and patients' characteristics.ResultsThe median values of serum S100A12 levels were 68.2 ng/mL (range: 43.4-147.4) in UC, 70 ng/mL (41.4-169.8) in CD and 43.4 ng/mL (34.4-74.4) in IBS patients. UC and CD patients had significantly higher serum S100A12 levels compared to IBS patients (P = 0.001 for both comparisons). Moreover, a cut-off for serum S100A12 levels of 54.4 ng/mL could predict both UC and CD with a 66.7% sensitivity and a 64.4% specificity. The area under curve was estimated at 0.67 with a 95% confidence interval of 0.60-0.75 (P < 0.001). Considering standard activity indices, higher serum S100A12 levels in active compared to inactive IBD were observed, although the recorded difference did not reach statistical significance. C-reactive protein (CRP) and serum amyloid A (SAA) levels, showed a statistically significant positive correlation with S100A12 (r = 0.39, P = 0.001 and r = 0.23, P = 0.02 respectively).ConclusionsIncreased levels of circulating S100A12 are found in IBD, compared to IBS. When used to distinguish IBD from IBS adult patients, serum S100A12 levels exhibit moderate performance. On the other hand, serum S100A12 may serve as an inflammatory marker in IBD, since it is well correlated with CRP and SAA.

【 授权许可】

Unknown   
© Manolakis et al; licensee BioMed Central Ltd. 2010. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.